A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Sep 2020 Results evaluating the impact of renal impairment on the pharmacokinetics of Glasdegib presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 26 Sep 2018 Status changed from recruiting to completed.